A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Clinical trial NCT07482657 · RECRUITING

Trial details

NCT number: NCT07482657
Sponsor: Enanta Pharmaceuticals, Inc
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

RSV Infection RSV Respiratory Syncytial Virus (RSV)

Start date: 2026-07-09
Primary completion: 2026-12-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.